{"id":385445,"date":"2020-11-19T13:03:18","date_gmt":"2020-11-19T18:03:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=385445"},"modified":"2020-11-19T13:03:18","modified_gmt":"2020-11-19T18:03:18","slug":"investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/","title":{"rendered":"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors"},"content":{"rendered":"

<\/p>\n

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors <\/b><\/p>\n

BENSALEM, Pa.–(BUSINESS WIRE<\/a>)–
\nLaw Offices of Howard G. Smith announces an investigation on behalf of Biogen, Inc. (\u201cBiogen\u201d or the \u201cCompany\u201d) (NASDAQ: BIIB<\/a>) investors concerning the Company\u2019s possible violations of federal securities laws.\n<\/p>\n

\nBiogen develops therapies for treating neurological and neurodegenerative diseases. One of its product candidates is aducanumab (BIIB037), an investigational human monoclonal antibody studied for use as a treatment for early Alzheimer\u2019s disease.\n<\/p>\n

\nOn October 22, 2019, the Company announced that it would seek regulatory approval from the U.S. Food and Drug Administration (\u201cFDA\u201d) for aducanumab \u201cbased on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019 following a futility analysis.\u201d According to Biogen, the new analysis \u201cshow[ed] that aducanumab is pharmacologically and clinically active as determined by dose-dependent effects in reducing brain amyloid and in reducing clinical decline as assessed by the pre-specified primary endpoint Clinical Dementia Rating-Sum of Boxes (CDR-SB).\u201d\n<\/p>\n

\nOn November 6, 2020, Reuters<\/i> reported that an FDA panel found it \u201ccannot ignore unsuccessful trial data on Biogen Alzheimer\u2019s drug.\u201d The panel had also \u201cvoted that an earlier-stage study does not offer supportive evidence of Biogen\u2019s application for the drug, aducanumab.\u201d\n<\/p>\n

\nOn this news, the Company\u2019s stock price fell $92.64 per share, or 28%, to close at $236.26 per share on November 9, 2020, thereby injuring investors.\n<\/p>\n

\nIf you purchased Biogen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com<\/a>, or visit our website at www.howardsmithlaw.com<\/a>.\n<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201119005378\/en\/<\/a><\/span><\/p>\n

\nLaw Offices of Howard G. Smith
\n
Howard G. Smith, Esquire
\n
215-638-4847
\n
888-638-4847
\n
howardsmith@howardsmithlaw.com
\n<\/a>
www.howardsmithlaw.com<\/a><\/p>\n

KEYWORDS:<\/b> California Pennsylvania United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors BENSALEM, Pa.–(BUSINESS WIRE)– Law Offices of Howard G. Smith announces an investigation on behalf of Biogen, Inc. (\u201cBiogen\u201d or the \u201cCompany\u201d) (NASDAQ: BIIB) investors concerning the Company\u2019s possible violations of federal securities laws. Biogen develops therapies for treating neurological and neurodegenerative diseases. One of its product candidates is aducanumab (BIIB037), an investigational human monoclonal antibody studied for use as a treatment for early Alzheimer\u2019s disease. On October 22, 2019, the Company announced that it would seek regulatory approval from the U.S. Food and Drug Administration (\u201cFDA\u201d) for aducanumab \u201cbased on a new analysis, conducted by Biogen in consultation with the FDA, of … <\/p>\n

Continue reading “INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-385445","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors BENSALEM, Pa.–(BUSINESS WIRE)– Law Offices of Howard G. Smith announces an investigation on behalf of Biogen, Inc. (\u201cBiogen\u201d or the \u201cCompany\u201d) (NASDAQ: BIIB) investors concerning the Company\u2019s possible violations of federal securities laws. Biogen develops therapies for treating neurological and neurodegenerative diseases. One of its product candidates is aducanumab (BIIB037), an investigational human monoclonal antibody studied for use as a treatment for early Alzheimer\u2019s disease. On October 22, 2019, the Company announced that it would seek regulatory approval from the U.S. Food and Drug Administration (\u201cFDA\u201d) for aducanumab \u201cbased on a new analysis, conducted by Biogen in consultation with the FDA, of … Continue reading "INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T18:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors\",\"datePublished\":\"2020-11-19T18:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/\"},\"wordCount\":402,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/\",\"name\":\"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-11-19T18:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors - Market Newsdesk","og_description":"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors BENSALEM, Pa.–(BUSINESS WIRE)– Law Offices of Howard G. Smith announces an investigation on behalf of Biogen, Inc. (\u201cBiogen\u201d or the \u201cCompany\u201d) (NASDAQ: BIIB) investors concerning the Company\u2019s possible violations of federal securities laws. Biogen develops therapies for treating neurological and neurodegenerative diseases. One of its product candidates is aducanumab (BIIB037), an investigational human monoclonal antibody studied for use as a treatment for early Alzheimer\u2019s disease. On October 22, 2019, the Company announced that it would seek regulatory approval from the U.S. Food and Drug Administration (\u201cFDA\u201d) for aducanumab \u201cbased on a new analysis, conducted by Biogen in consultation with the FDA, of … Continue reading \"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T18:03:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors","datePublished":"2020-11-19T18:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/"},"wordCount":402,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/","name":"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-11-19T18:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201119005378r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-alert-law-offices-of-howard-g-smith-announces-investigation-of-biogen-inc-biib-on-behalf-of-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen, Inc. (BIIB) on Behalf of Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=385445"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385445\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=385445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=385445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=385445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}